Pfizer Inc. (PFE)
Pfizer: Still Mispriced By Mr. Market (Earnings Preview)
Pfizer remains a Buy, with a 16% nominal upside and ~7% dividend yield, driven by a diversified, expanding product portfolio. PFE's new growth portfolio, cost controls, and business reorganization are offsetting LOEs and COVID-related sales declines, supporting forward EPS stability. Upcoming Q2 earnings are expected to beat conservative consensus, with management updates on pipeline and product launches as key catalysts.
Pfizer (PFE) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Pfizer said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in two late-stage trials, paving the way for regulatory submissions seeking approval in the autoimmune skin disease.
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far
I initiate Pfizer with a contrarian BUY rating and a $32 price target for 2026 Q3-Q4. PFE's non-COVID portfolio demonstrates resilience, with Padcev, Vyndamax, and new launches driving operational growth despite patent cliffs. Padcev's July 2026 approval expands its addressable market, while pipeline assets like Berobenatide and PF-08634404 offer additional upside.
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.
Pfizer's prostate cancer drug combination gets US FDA priority review
Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
